Stack Financial Management’s Bristol-Myers Squibb BMY Stock Holding History

Stack Financial Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-176,827	Closed	-$10.3M	–	43
2023 Q3	$10.3M	Buy	176,827 +2,314	+1%	+$142K	1.2%	35
2023 Q2	$11.2M	Buy	174,513 +3,581	+2%	+$240K	1.25%	33
2023 Q1	$11.8M	Buy	+170,932	New	+$12.1M	1.44%	31

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Stack Financial Management's BMY Position: Q4 2023 in Review

Stack Financial Management sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 176,827 shares — an estimated $10.3M sold.

Stack Financial Management first reported a position in BMY in Q1 2023 and held it in 3 quarters. The position peaked at $11.8M in Q1 2023. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Stack Financial Management reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Stack Financial Management sold 176,827 Bristol-Myers Squibb shares in Q4 2023, an estimated $10.3M.
Stack Financial Management first reported a position in Bristol-Myers Squibb in Q1 2023 and held it in 3 quarters.
Stack Financial Management's Bristol-Myers Squibb position peaked at $11.8M in Q1 2023.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Stack Financial Management's 13F filing for Q4 2023, filed 2 Feb 2024.